TW246670B - - Google Patents

Info

Publication number
TW246670B
TW246670B TW082105933A TW82105933A TW246670B TW 246670 B TW246670 B TW 246670B TW 082105933 A TW082105933 A TW 082105933A TW 82105933 A TW82105933 A TW 82105933A TW 246670 B TW246670 B TW 246670B
Authority
TW
Taiwan
Application number
TW082105933A
Other languages
Chinese (zh)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of TW246670B publication Critical patent/TW246670B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/64—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW082105933A 1992-07-27 1993-07-26 TW246670B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929215921A GB9215921D0 (en) 1992-07-27 1992-07-27 Anti-inflammatory compounds

Publications (1)

Publication Number Publication Date
TW246670B true TW246670B (enExample) 1995-05-01

Family

ID=10719360

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082105933A TW246670B (enExample) 1992-07-27 1993-07-26

Country Status (10)

Country Link
EP (1) EP0652864A1 (enExample)
JP (1) JPH07509462A (enExample)
AU (1) AU672810B2 (enExample)
CA (1) CA2141214A1 (enExample)
GB (1) GB9215921D0 (enExample)
IL (1) IL106472A0 (enExample)
MX (1) MX9304503A (enExample)
TW (1) TW246670B (enExample)
WO (1) WO1994002448A1 (enExample)
ZA (1) ZA935378B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283564B6 (cs) * 1993-11-26 1998-05-13 Pfizer Inc. 3-Aryl-2-isoxazolin-5-hydroxamové kyseliny a farmaceutické prostředky na jejich bázi
MX9603943A (es) * 1994-03-09 1997-04-30 Pfizer Compuestos de isoxazolina como inhibidores de 5-lipooxigenasa.
WO1996023772A1 (en) * 1995-02-02 1996-08-08 Nikken Chemicals Co., Ltd. N-hydroxyurea derivatives
ES2243978T3 (es) 1996-02-13 2005-12-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4.
WO1997029776A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
AU1952597A (en) 1996-02-13 1997-09-02 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
AU721942B2 (en) * 1996-06-25 2000-07-20 Cephalon, Inc. Use of K-252A derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
DK1001930T3 (da) * 1997-07-31 2003-03-24 Abbott Lab N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
WO2000044712A1 (en) * 1999-01-27 2000-08-03 Abbott Laboratories N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
SE0103325D0 (sv) 2001-10-04 2001-10-04 Astrazeneca Ab Novel compounds
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559699B2 (ja) * 1985-03-16 1996-12-04 ザ ウエルカム フアウンデ−シヨン リミテツド 新規なアリ−ル誘導体
PL154186B1 (en) * 1987-07-15 1991-07-31 Wellcome Found Method for manufacturing arylic derivatives of the hydroxamic acid
DK0540673T3 (da) * 1990-07-25 1997-03-24 Abbott Lab Acetylen-derivater med lipoxygenaseinhiberende virkning
JPH06256285A (ja) * 1990-12-11 1994-09-13 Pfizer Pharmaceut Co Ltd ヒドロキサム酸誘導体およびその用途

Also Published As

Publication number Publication date
ZA935378B (en) 1995-01-26
AU4717093A (en) 1994-02-14
MX9304503A (es) 1994-04-29
GB9215921D0 (en) 1992-09-09
IL106472A0 (en) 1993-11-15
EP0652864A1 (en) 1995-05-17
AU672810B2 (en) 1996-10-17
CA2141214A1 (en) 1994-02-03
JPH07509462A (ja) 1995-10-19
WO1994002448A1 (en) 1994-02-03

Similar Documents

Publication Publication Date Title
TW221316B (enExample)
DK0553875T3 (enExample)
TW260666B (enExample)
DK0630289T3 (enExample)
TW240240B (enExample)
FR2687517B1 (enExample)
DK0599160T3 (enExample)
DK0644844T3 (enExample)
DK0588007T3 (enExample)
DK0581129T3 (enExample)
AU1708392A (enExample)
FR2690655B1 (enExample)
TW238267B (enExample)
DK0581726T3 (enExample)
AU632452B2 (enExample)
AU633801B1 (enExample)
AU634140B1 (enExample)
AU634143B1 (enExample)
AU639661B1 (enExample)
AU639200B1 (enExample)
AU1849392A (enExample)
EP0591809A3 (enExample)
AU1933792A (enExample)
AU2202592A (enExample)
AU1281292A (enExample)